Apellis Pharmaceuticals Inc Q2 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Just first on the ION. Can you just elaborate on the cases that we're seeing, I guess, how the patients presented and how they were managed and I guess, if it was resolved? And then also specifically, I think in one of the first questions on the call, you mentioned some comorbidities that the patients had. If you could just kind of elaborate on this and maybe why this sort of leads you to think that this was not drug-related in those cases seen? And then just second question, just in terms of thinking about the real-world potential duration of use of anti-VEGF in the cases of sort of new onset exudation, maybe just how you're thinking about that? And how long anti-VEGF might be used in those cases? And I guess, if there's any data that we can expect such as from the 24-month data or I'm thinking about sort of the longer term GALE study about sort of the management of the new onset exudations and thinking about the duration of use of the anti-VEGF.